TL;DR — AMA HOD 2026 is two meetings: the Annual Meeting runs June 5–10, 2026 at the Hyatt Regency Chicago, and the Interim Meeting runs November 6–10, 2026 at the Walt Disney World Swan and Dolphin Resort in Orlando. Roughly 700 delegates representing state medical associations, specialty societies, federal services, and AMA sections debate and adopt the policy positions that shape how American medicine practices, bills, and regulates itself. There is no exhibit hall. Healthcare brands engage HOD through specialty society sponsorships, the AMA corporate roundtable, AMA Foundation support, JAMA-published evidence, and direct relationships with delegation leaders. The ROI is influence on national policy — payment reform, prior authorization, AI in clinical practice, scope of practice — not booth leads. Treat HOD as the most concentrated physician-policy audience in the country, plan twelve months in advance, and measure success in cited resolutions and policy alignment rather than badge scans.

What AMA HOD Is — and Why It Matters to Healthcare Brands

The American Medical Association House of Delegates is the legislative and policymaking body of the AMA. Twice each year, roughly 700 delegate physicians convene to debate resolutions, set the organization's policy positions, and elect AMA leadership. What they vote on becomes AMA policy, and AMA policy becomes the official physician-community position on the issues that drive payment, regulation, and clinical practice across U.S. medicine: Medicare physician payment, prior authorization, artificial intelligence in clinical care, scope of practice for non-physician providers, drug pricing, Medicaid expansion, telehealth, and physician workforce.

For medical device manufacturers, pharmaceutical companies, digital health vendors, and healthcare technology platforms, that policy output is not academic. AMA policy positions are routinely cited by CMS in rulemaking, by state legislatures debating scope-of-practice laws, by specialty societies aligning their own positions, and by health systems writing internal clinical guidelines. A favorable AMA position on a category — augmented intelligence, remote patient monitoring, non-opioid pain management, biosimilar substitution — is worth more in regulatory and adoption leverage than almost any individual KOL endorsement.

That is the strategic case for paying close attention to AMA HOD. It is also why HOD does not look or feel like the trade shows most healthcare marketers are used to. There is no exhibit hall, no booth program, no badge-scanner-driven lead funnel. The audience is small, but it is the most concentrated physician-policy audience in the country, and the engagement model is built on influence, not interruption.

AMA HOD 2026: The Numbers You Need

Two meetings per year matters for planning. The June Annual Meeting is the larger and more procedurally important of the two — full elections, the President-Elect cycle, the bulk of new resolutions, and the most extensive media coverage. The November Interim Meeting is shorter and more focused, often used to react to fast-moving regulatory and legislative developments from the year. Brands that engage HOD seriously plan for both, because a policy thread introduced at Interim frequently matures into adopted policy at the following Annual.

Who Is Actually in the Chamber

Understanding the delegate composition is the first move. The HOD is not a random sample of practicing physicians — it is a curated mix of organizational representatives.

State medical associations are allocated delegates based on AMA membership in each state. State delegations are typically led by long-serving practicing physicians who are deeply involved in state-level advocacy, scope-of-practice fights, Medicaid policy, and physician-licensure issues. They tend to be generalists across health policy with a strong state-political lens.

National medical specialty societies — the American College of Cardiology, the American College of Surgeons, the American College of Radiology, the American College of Physicians, the American Academy of Family Physicians, the American Academy of Ophthalmology, and dozens more — send delegations that represent specialty-specific clinical and economic concerns. If your product or category has a clear specialty home, these delegations are usually your highest-leverage relationships.

AMA sections represent demographic and career-stage segments of the membership: medical students, residents and fellows, young physicians, senior physicians, women physicians, international medical graduates, minority affairs, and integrated physician practice. Sections are increasingly influential on issues like burnout, wellness, equity, and workforce sustainability.

Federal services delegations represent military, Public Health Service, and Veterans Affairs physicians. They carry real weight on issues at the intersection of clinical practice and federal policy — telehealth licensure, AI procurement, controlled substance prescribing, and emergency preparedness.

Professional interest medical associations include the American Medical Women's Association (AMWA), the American Osteopathic Association (AOA), and the National Medical Association (NMA), among others. They expand the policy conversation across communities the state and specialty delegations do not always represent.

For commercial brands, the practical takeaway is that you cannot engage AMA HOD as one undifferentiated audience. You engage specific delegations whose clinical specialty, geographic footprint, or section interest aligns with your category — and you build those relationships over years, not weeks. A focused primary care physician marketing strategy or emergency medicine marketing approach often opens the relevant specialty society door first.

Why HOD Is Not a Trade Show — and What That Changes

Healthcare marketers who treat HOD like HIMSS, RSNA, or AAOS will spend money badly. There is no booth program. There is no general exhibit floor. There is no badge-scanner-driven lead funnel. The procedural rhythm of the meeting — reference committee hearings, caucus deliberations, plenary debate, elections — does not produce floor-traffic moments the way a clinical conference exhibit hall does.

What HOD produces instead is a five- to six-day concentration of physician-policy decision-makers in a single hotel, with structured time for caucusing, networking, and informal relationship-building outside the formal sessions. That is the engagement surface. Companies that win at HOD do not buy presence — they invest in relationships that mature over multiple meeting cycles.

This is closer to the engagement model of a major political party convention than a clinical trade show. The marketing playbook from our medical conference playbook still applies for surrounding events and pre-meeting outreach, but the on-site execution is fundamentally different. You are not capturing leads. You are reinforcing relationships and contributing to policy conversations the delegates are already having.

Five Real Engagement Strategies for HOD 2026

1. Sponsor specialty society caucus meetings and dinners

Most national specialty societies hold caucus meetings and delegation dinners during HOD. Sponsoring a caucus meeting, hosting a delegation dinner, or supporting a specialty society reception puts your brand in front of the exact 30–80 delegates who shape that specialty's HOD positions. The value is concentrated relationship time with the people who will speak at reference committee, draft amendments, and vote on the issues that matter to your category. Engagement decisions here are usually made through the specialty society directly — not through the AMA — and they require 6–12 months of planning lead time.

2. Join the AMA corporate roundtable

The AMA's corporate roundtable program gives sustaining corporate members structured access to AMA leadership and to organizational priorities throughout the year. For companies whose product or category is regularly the subject of AMA policy — augmented intelligence, prior authorization technology, value-based care platforms, opioid alternatives, biosimilars — the roundtable is the right place to make sure your category is represented thoughtfully in AMA strategic conversations. It does not buy a HOD vote, but it earns standing.

3. Support AMA Foundation programs aligned with your therapeutic area

The AMA Foundation funds physician wellness, public health education, and medical student support programs. Sponsoring or partnering on Foundation initiatives in your therapeutic area — mental health, women's health, rural workforce, opioid recovery, diabetes management — builds long-term goodwill with AMA leadership and creates natural touchpoints at HOD around Foundation events. This is patient-centered advocacy-group partnership work at the physician-organization level, and it pays dividends for years.

4. Publish peer-reviewed evidence in JAMA family journals

JAMA, JAMA Internal Medicine, JAMA Surgery, JAMA Network Open, and the rest of the JAMA family are the most-cited general medical journals in the country. Evidence published there is disproportionately likely to be cited in reference committee hearings, in resolution rationales, and in AMA policy statements. For brands with rigorous clinical or health economics data, getting that data into a JAMA family journal eighteen months ahead of an anticipated policy debate is one of the highest-leverage investments in physician-policy influence available.

5. Build relationships with delegation leaders year-round

The state and specialty society delegation chairs are publicly identifiable. They publish. They speak at state and specialty meetings. They have LinkedIn presences and association leadership roles. A focused LinkedIn-led thought leadership program that engages 30–50 delegation leaders authentically over twelve months — sharing clinical evidence, surfacing real practice problems, supporting their initiatives — builds the kind of standing that matters when your category is debated on the floor. Use KOL program discipline here, not transactional outreach.

Common Mistakes Brands Make at AMA HOD

Booking last-minute and expecting access. HOD relationships are built over 12–24 months. A pharmaceutical or device company that decides in March 2026 to "get involved at HOD in June 2026" will find every caucus sponsorship already committed, every reception calendar locked, and every delegation chair already in conversation with last year's relationship investors. Plan the 2027 cycle now, and the 2028 cycle alongside it.

Talking only to physicians and ignoring association staff. Specialty society and state medical association staff frequently drive the operational calendar — which resolutions get heard, which speakers get floor time at caucus, which sponsorships get accepted. Treat association executive directors and policy staff as first-class stakeholders, not gatekeepers.

Pitching product instead of policy. HOD delegates are at the meeting to set policy, not to evaluate vendors. Brands that arrive with a product pitch get dismissed; brands that arrive with a thoughtful position on a policy issue the delegates are actively debating — backed by real evidence — get heard. Lead with the policy thesis, not the product story.

Underestimating the Interim Meeting. November's Interim Meeting is shorter and lower-profile than June's Annual, but it is often where policy threads originate. A resolution introduced and referred at Interim frequently becomes adopted policy at the following Annual. Brands that only engage the Annual Meeting miss half the policy arc.

Skipping evidence preparation. Reference committee hearings reward delegates and outside testimony backed by citations. A category position memo with strong peer-reviewed evidence and balanced consideration of opposing views is the format that influences policy. A glossy product brochure is the format that gets ignored.

How to Measure ROI from HOD Engagement

Standard conference marketing ROI — leads, qualified meetings, attributable pipeline — does not map cleanly to HOD. The right metrics are policy-aligned and longer-cycle, more like the framework in our conference marketing ROI guide applied to policy outcomes rather than booth pipeline.

None of these metrics produce a clean quarterly dashboard. All of them produce real, durable, regulatory-relevant influence over multi-year cycles. For categories where AMA policy directly affects payment, adoption, or scope of practice, the math is usually obvious — even though it is patient.

Should Your Brand Engage AMA HOD 2026?

Yes, if AMA policy positions materially affect your category. That includes most medical devices in regulated specialties, most pharmaceuticals with prior authorization or coverage exposure, most digital health and AI platforms in clinical workflow, most telehealth and remote monitoring products, and most products at the intersection of physician practice economics and clinical care. If a CMS rulemaking, a state scope-of-practice fight, or a specialty society guideline could meaningfully move your business, HOD belongs in your policy and marketing calendar.

No, if your audience is purely consumer or purely employer-paid, if your product is sold entirely outside the U.S. regulated medical channel, or if AMA policy positions have demonstrably no influence on your buyers. For those brands, the budget belongs in clinical conferences with active exhibit floors and direct commercial decision-makers — not in HOD relationship investment.

If you're in the gray zone — your product is regulated, your buyers are physicians, AMA has occasionally weighed in on adjacent issues — run a focused twelve-month pilot. Sponsor one specialty society caucus dinner in 2026. Attend the Annual Meeting and Interim Meeting as a credentialed observer. Build relationships with three to five delegation leaders. Publish one peer-reviewed piece of category-relevant evidence. Then measure invitation flow, citation visibility, and policy alignment in 2027 against your baseline. That pilot tells you whether sustained HOD engagement belongs in your category strategy, with real evidence and at a fraction of the cost of a misaligned multi-year commitment.